Search
Find the right content for you
Much Ado About Nothing
For a long time, a source of tension among UK trade mark and design attorneys was the fact that the UK was one of the few EU member states to abide by a decision to allow attorneys from any European Economic Area country to represent clients in proceedings before any national office of an EU member state. With this in mind, one of the ironies of Brexit is that, from 1st January 2021, UK trade mark and design attorneys will (in general – please see below for a super-important exception!) lose the right to represent clients before the EU IPO
The impact of Artificial Intelligence and Machine Learning on the Patent Profession
Matthew Veale discusses the impact of Artificial Intelligence and Machine Learning on the patent profession.
Top Cat helps Dibble nab Copy Cats
It’s news that could make Amazon the most tip top Top Cat among toy and game designers, inventors and parents worldwide. The retailer has announced the establishment of a Counterfeit Crimes Unit that will be tasked with bringing copycats to justice. The Counterfeit Crimes Unit is composed of former federal prosecutors, data analysts and investigators and will be charged with bringing sellers that break not only law, but Amazon’s policies, to justice.
European Patent Scam Payment Letters
Have you received a letter out-of-the-blue recently from an unfamiliar agency asking you to pay a fee to register your European Patent application? Look out for the scam letters that look official, but aren't.
UK Supreme Court judgment: Regeneron v Kymab
On 24 June 2020, the UK Supreme Court handed down its landmark judgment in Regeneron Pharmaceuticals Inc v Kymab Ltd [2020] UKSC 27 in a dispute that has been rumbling on for seven years. It was good news for Kymab and bad news for Regeneron, which saw two of its patents invalidated. For the rest of us, it’s an important case which includes key rulings on insufficiency.
Is it unethical to patent?
The Covid-19 pandemic has prompted many companies to invest time and effort in developing technology that is aimed at helping care for, test, or treat people suffering from the disease. In normal times, these might be considered normal commercial activities and would be considered for patenting without a second thought. However, the fact that these developments are typically not being motivated by pure commercial gain, but by a desire to do something for the public good causes many companies to question whether or not they should seeks patents or any other form of intellectual property protection.
EBA issues decision on the patentability of plants and animals
On 14 May 2020, the Enlarged Board of Appeal (EBA) at the European Patent Office (EPO) issued its much-awaited decision G 3/19 on the patentability of plants and animals, otherwise known as “Pepper”.